| Name | Title | Contact Details |
|---|
The Odessa Roughnecks is a professional indoor football team based in Odessa, Texas. The teams nickname is a tribute to the oil industry, which has been the source of Odessas wealth over the past century. The team began operations in 2004 as a charter member of the Intense Football League. In 2005, the Intense Football League merged with the National Indoor Football League. For the 2006 season, the Intense Football League was resurrected, and the Odessa Roughnecks returned to their original league. In 2008 the Intense Football League merged again, this time with United Indoor Football to create the Indoor Football League. The team plays its home games at the Ector County Coliseum in Odessa. The teams founder and owner was Tommy Benizio until he resigned to become the IFLs commissioner. In September 2008, the Roughnecks were purchased by the ownership group Allegiance Pro Sports, Inc., led by President & CEO Brandon Smith, a Odessa native, local business owner and 1991 graduate of Odessa High School. The Roughnecks are coached by Chris Williams (former head coach of the Tennessee Valley Vipers of the af2 and was the Roughnecks first head coach). The 2009 season will be Coach Williamss sixth season with the Roughnecks. The Roughnecks won its first championship in 2006 at Intense Bowl 2, beating the Corpus Christi Hammerheads by a score of 97-56, which was an Intense Football League record for most points scored by one team in a game. The team finished with an overall record of 14-2.
Swagelok is a manufacturer and supplier of gas and fluid systems components.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.